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The purpose of this quality improvement project was to increase human papillomavirus 
vaccination series initiation rates among indigent women, ages 19-26, at a clinic in South Texas. 
The human papillomavirus is a sexually transmitted infection that has been associated with 
multiple types of cancers. Each year, approximately 6.2 million cases of the human 
papillomavirus infection are diagnosed; as many as 75% of all new infections occur among 
females 18-26 years of age. The human papillomavirus vaccination has a high efficacy in regards 
to cancer prevention, preventing as many as 76% of cancers with only one dose. The project 
included educating clinic staff about human papillomavirus vaccination guidelines, finding a 
funding source for the human papillomavirus vaccine and developing a protocol for aligning the 
providers with current guidelines and screening patients to identify vaccine eligible women. The 
population served at this clinic was primarily Hispanic (84%), 22 years of age, used no 
contraceptive methods (62%), was single (92%), with a high school diploma (56.9%).  Before 
initiation of the project, random chart audits of 50 human papillomavirus vaccination eligible 
women indicated that only one out of 50 received the human papillomavirus vaccination. During 
the project cycle, 21 of the 50 human papillomavirus vaccination eligible women received at 
least 1 dose of the vaccination, indicating clinical and statistical significance. The interventions 
implemented were effective in improving adherence to guidelines and improved vaccination 
rates by 40%. Stakeholder commitment to the project ensures sustainability. 
 Key Words: Human Papilloma Virus, vaccination, indigent health, women, cance
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Context of This Study 
 The human papillomavirus (HPV) is a sexually transmitted infection that has been 
associated with multiple types of cancers, most notably, cervical cancer (Hopfer, 2011). This 
pervasive infection has also been linked to vulvar, vaginal, penile, anogenital, and oropharyngeal 
cancer, as well as genital warts in both sexes (Centers for Disease Control and Prevention 
[CDC], 2014). Approximately 6.2 million cases of the human papillomavirus infection are 
diagnosed annually among females and males (Rosenthal et al., 2011). While HPV occurs in 
both sexes, as many as 75% of all new HPV infections annually occur among females 18-26 
years of age (Hopfer, 2011). Multiple studies have revealed a persistent inequality with regard to 
HPV vaccination rates in those who reside in the Southern United States, are considered 
socioeconomically disadvantaged, are Hispanic or another minority race/ethnicity, lack insurance 
coverage, are married, have less than a high school education, do not have a usual place of care, 
have not received other recommended vaccinations, have delayed or foregone healthcare, or are 
greater than 18 years of age (Lu, O’Halloran, & Williams, 2015; Rahman, Islam, & Berenson, 
2015; Schmidt & Parsons, 2014). Current practices at the clinical site where this quality 
improvement project took place, when compared to the national standardized clinical guidelines 
established by the Advisory Committee on Immunization Practices (ACIP), in regards to HPV 
vaccination, are not being met.  
Statement of the Problem 
 Currently, in the United States, HPV infections have been cited as the most common STI, 
with over 200 strains that have been examined (National Cancer Institute, 2015). Approximately 
14 million new infections of HPV occur annually, with an estimated 80%-90% of females and 
males, who are sexually active, contracting at least one strain of HPV at some point during their 
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lifetime (National Cancer Institute, 2015; CDC, 2014). Roughly, 50% of these infections will be 
with a high-risk strain of HPV (National Cancer Institute, 2015). High-risk strains of HPV have 
been associated with approximately 5% of all cancer cases globally (National Cancer Institute, 
2015). In the United States, high-risk strains of HPV have been linked to 3% of all cancer cases 
among females (National Cancer Institute, 2015).  
Background and Significance 
 According to the National Cancer Institute (2015), infection with HPV strains 16 and 18 
causes essentially all cases of cervical cancer. The burden caused by the HPV infection includes 
pre-cancers to cervical lesions (CDC, 2014). Cervical cancer accounts for approximately 70% of 
all cases of cancer (National Cancer Institute, 2015). Cancer of the anus is caused by HPV at a 
rate of 95%; of these cases HPV strain 16 is responsible (National Cancer Institute, 2015). An 
estimated 70% of cancers of the oropharyngeal structures (throat, soft and hard palate, tongue, 
and tonsils) are caused by infection with HPV (National Cancer Institute, 2015). Currently, half 
of the cancers caused in the oropharyngeal structures in the United States, are associated with 
HPV strain 16 (National Cancer Institute, 2015). Infection with HPV also has been shown to 
cause vaginal cancers, vulvar cancers, and penile cancers; many of these have been linked to 
HPV strain 16 (National Cancer Institute, 2015). The estimated percentage of cases caused by 
HPV are 65%, 50%, and 35%, respectively (National Cancer Institute, 2015). 
 According to the CDC (2014), the introduction of the Gardasil 9-valent vaccination has 
been shown to be cost-effective, despite the cost of $13.00 more per dose, when compared to the 
bi-valent, and quadrivalent vaccinations. According to Jit, Brisson, Portnov, and Hutubessy 
(2014), in a study conducted in 179 countries, vaccinating a cohort composed of 58 million girls, 
age 12, showed the HPV vaccination to be cost-effective by preventing an estimated 690,000 
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cases of cervical cancer, and 420,000 deaths during their lifetime, at a net cost of $4 billion U.S. 
dollars (Jit et al., 2014). Most of girls in the study were in primarily low or middle income 
countries (Jit et al., 2014). The study showed evidence for the HPV vaccination, that with every 
quality adjusted life year, costs were found to be less than the gross domestic product per head in 
87% of these countries (Jit et al., 2014).  
 Despite ample information displaying the safety and efficacy of the HPV vaccination, a 
severe deficit in vaccination initiation and completion is seen in women between the ages of 18-
26 (Schmidt & Parsons, 2014). The HPV vaccination, Gardasil 9, has a 98% efficacy against 
cervical cancer, 100% efficacy against vulvar and vaginal cancer, 100% against anal cancer, 75% 
efficacy against genital warts, and an overall 99% efficacy in females according to a study cited 
on Merck Vaccines (2015) website. As much as 76% to 100% efficacy can be noted with just 
one dose of the HPV vaccination (Kreimer, 2011).  
Assessment 
A hospital-based family health center in South Texas was the site for implementation of 
this evidence-based quality improvement project related to increasing the HPV vaccination rates 
in women, 19-26 years of age, and providers' adherence to the CDC and ACIP clinical 
guidelines. The staff involved in this project included the providers (1.0 physician, 1.0 family 
nurse practitioner), three licensed vocational nurses, two front office clerks, two medical 
assistants, the medical records personnel, and a registered nurse, who holds the office manager 
position.  
The South Texas based clinic currently provides care to approximately 7,000 patients 
annually, and treats patients 18 years of age and older. From March 2016 to March 2017, 
approximately 300 women, ages 19 to 26, were treated at the clinic. 
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A May 2017 microsystem assessment indicated the clinic has a high percentage of 
women who are at an increased risk for acquiring HPV based on their history and physical 
examination results documented in the electronic health record. As of the present, only 2% of 
women in the 19-26 age range have initiated the HPV vaccination series according to a pre-
intervention chart audit of 100 women seen within the last year. However, according to Bennett 
et al. (2015), guidelines presented by the ACIP, since 2007, recommend initiating the HPV 
vaccination series on girls ages 11-12, and implementing the catch up series for females, ages 
13-26. The aim of this quality improvement project was to improve rates the of the HPV 
vaccination series initiation from 2% to 30% in indigent women serviced at the clinic, ages 19-
26, in a 10 week period between June 2017 and August 2017. Currently, evidence-based 
benchmark data on HPV vaccination uptake in women ages 19-26 is limited.  
While the majority of the patients spoke Spanish as their primary language, many were 
bilingual, and a small percentage spoke only English. Of the providers, the nurse practitioner 
speaks fluent Spanish, while the physician utilizes a translator. Fortunately, for the clinic, many 
of the staff members, including two licensed vocational nurses, two medical assistants, the office 
manager, and front desk clerks, all spoke fluent Spanish.  
Most of the women who received care at this clinic were of lower socioeconomic class, 
with as many as 51% of these individuals earning a household income of less than $34,999 a 
year (Acosta et al., 2014). The mean age of the pre-intervention group was 22.30 years of age. Of 
the sample size, there were 11 women who were 19 years of age, 12 who were 20 years of age, 
14 who were 21 years of age, 17 who were 22 years of age, 8 who were 23 years of age, 13 who 
were 24 years of age, 13 who were 25 years of age, and 12 who were 26 years of age.  
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The top two payer sources of the pre-intervention chart audit was the Nueces County 
Hospital District (NCHD) at 84% and Medicaid, at 14%. Nearly 84% of these women identified 
as themselves as Hispanic. The pre-intervention chart audit also identified 62% of women were 
up-to-date with their annual pap smears, 62% used no form of contraception, 18% have a history 
of a STI, 30% have a history of an abnormal pap smear, 86% are single, and 54% have a high 
school diploma, or equivalent. 96% of these women identified as heterosexual. 
Due to funding, the clinic did not routinely vaccinate women ages 19-26, who are at risk 
for acquiring the HPV strains prevented by the vaccination. 
Organization's Readiness for Change 
 Upon review of the CDC and ACIP guidelines, and the results provided from the May 
2017 microsystem assessment with key stakeholders, it was determined that the family health 
center was not aligned with the CDC and ACIP guidelines. Prior to review of the clinical 
guidelines, the clinic's providers were not aware of the age range for the HPV catch-up series for 
vaccination; they were also not aware of a way to obtain funding to provide the HPV 
vaccinations, at little to no cost to the clinic or their patients. Following review of the guidelines 
for HPV vaccination, it was determined that due to the high-risk population, an algorithm and 
protocol to align the clinic with the current clinical guidelines was needed. All clinic providers 
and staff expressed eagerness to engage in a project to implement the latest evidence-based CDC 
and ACIP guidelines for HPV vaccination in the clinic as a mechanism of improving the 
standard and quality of patient care. 
 Collaborating with the providers and the office manager, an algorithm was designed and 
established to identify women who were at risk for acquiring HPV, and could receive the HPV 
vaccination. The evidence from the appraisal was shared with the providers, citing that a strong 
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recommendation in favor of the HPV vaccination appeared to be the best approach to increasing 
vaccination rates. 
 Costs of the HPV vaccination appeared to be the primary barrier to increasing HPV 
vaccination rates at this clinic. However, a funding source, the Merck Patient Vaccine Assistance 
Program, appeared to be a low cost solution to improving acquisition of the vaccine. The 
program requires the clinic to purchase the first 10 vaccinations, fill out a Merck Patient Vaccine 
Assistance application on each patient who can receive the vaccination, and then the application 
is either approved or denied. Once 10 patients have been approved, the program replenishes 
the10 vaccines at no cost to the clinic. This will continue as long as the clinic wishes to 
participate in the program, and as long as a patient application is faxed and approved by Merck. 
Qualifications to participate include patients who do not have any form of health insurance, and 
make less $48,240 for a household of one (household income and those living in the household 
was adjusted, as income increases and occupants in the household increases). Due to the type of 
population serviced at the indigent health center, it was determined that the majority of patients 
who meet the criteria for vaccination, would qualify for the program.  
 Buy-in from the office manager, providers, and clinic staff was received openly, as it was 
a benefit for all involved. By increasing the women vaccinated, an increased number of nurse 
visits were scheduled for vaccination. An increase in nurse visits for the clinic was reflected in 
overall visit numbers, assisting the clinic to meet their annual goal of patients seen per year. 
Project Identification 
Purpose 
 The purpose of this evidence-based quality improvement project was to increase HPV 
vaccination series initiation rates among indigent women in South Texas, ages 19-26, through 
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provider recommendation, clinic funding, and provider adherence to the Centers for Disease 
Control and Prevention and The Advisory Committee on Immunization Practices guidelines, 
thereby improving the quality of care provided. 
Objectives 
 The objectives of this evidence-based project to improve the quality of care provided 
were to: 
 1. Increase HPV vaccination series initiation rates and compliance from the pre-
 intervention rate of 2% to 30% by the completion of the 10th week of project 
 implementation. 
 2. Increase clinic funding for the HPV vaccination by participating in the Merck Patient 
 Vaccine Assistance Program for the Gardasil 9-valent vaccination. 
 3. Appropriately train staff on the process and procedures of the Merck Patient Vaccine 
 Assistance Program, as well as the current guidelines established by the CDC and ACIP. 
 4. Increase the amount of times the providers provide a strong recommendation in favor 
 of the HPV vaccination to female patients, between 19-26 years of age, and have not 
 received any doses of the vaccination, or have not completed the vaccination series (3-
 doses).  
Anticipated Outcomes 
 By meeting the above stated objectives, the outcome of increasing the rate of HPV 
vaccination initiation and compliance from a pre-intervention rate of 2% to 30% by the 
completion of the 10th week of the project's implementation, occurred. Additional outcomes 
included the HPV vaccination being readily available in the office, as more funding was 
available to stock the vaccination. As a result of improved vaccination rates, women who 
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received the HPV vaccination will have a decreased morbidity and mortality rate, secondary to 
HPV and potential cancers. The overall outcome of this evidence-based quality improvement 
project was to increase the percentage of indigent women in South Texas, ages 19-26, who 
receive the HPV vaccination from 2% to 30%, as well as increased clinician adherence and 
compliance to the CDC and ACIP guidelines. The clinic aligned with Healthy People 2020 goals 
(2014) for increasing immunization rates, thereby directly reducing preventable, infectious 
diseases. 
Summary and Strength of the Evidence 
 Numerous research studies were appraised to identify the best methods of increasing 
HPV vaccination rates in women, ages 19-26 years of age, who have access to health care 
through indigent services, as well as increasing the providers' knowledge and adherence to the 
CDC and ACIP guidelines. The information which yielded the best evidence was synthesized, 
utilized to devise a system to increase HPV vaccination rates, and was then implemented.   
 Physician recommendation has a substantial influence on individuals initiating the HPV 
vaccination series (Vadaparampil et al., 2014). According to Rosenthal et al., (2011), receiving a 
strong physician recommendation to initiate the HPV vaccination series could result in up to a 
four-fold greater likelihood of vaccination. In another study by Ylitalo, Lee, and Mehta (2013), 
with a sample size of 9,274, greater than half of the study population who received a strong 
physician recommendation were almost five times as likely to initiate the HPV vaccination 
series. Furthermore, the strong association between physician recommendation and vaccination 
initiation translated across all races and ethnicities (Ylitalo et al., 2013). According to Ylitalo et 
al. (2013), after receiving a strong physician recommendation in favor of the HPV vaccination, 
both non-Hispanic Whites, as well as those who identify as White, were equally likely to obtain 
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vaccination. Women, ages 19-26, who had discussed uptake of the HPV vaccination with their 
health care provider, and received a strong recommendation, were significantly more likely to 
receive the vaccination (Rosenthal et al., 2011).  
 Current evidence suggests that other strategies are needed to increase and improve HPV 
vaccination uptake (Rosenthal et al., 2011). There is a lack of evidence detailing effective 
interventions to improve HPV vaccination coverage in women, ages 19-26. However, multiple 
studies suggest focusing on the patient, the health care provider's attitude towards HPV 
vaccination, health insurance status, marital status, education level, race and ethnicity, as well as 
current or prior infection with HPV (Bennett et al., 2015; Hopfer, 2011; Lu et al., 2015; Patel et 
al., 2012; Rosenthal et al., 2011; Wilson et al., 2016). Furthermore, many studies lack 
participation of the minority populations, individuals of lower socioeconomic class, those who 
are uninsured, have not completed a college degree, and are of 19-26 years of age (Bennett et al., 




 A pre-intervention chart audit was performed on 100 patients who meet the criteria for 
vaccination, seen in the clinic between March 2016 to March 2017. The data obtained reflected 
that of the women who could receive the vaccination, only 2% had been vaccinated, and 
completed the 3 dose series.  
 Prior to implementation, a one-on-one educational session was conducted with each 
provider and staff member on the current guidelines of administering the HPV vaccination, the 
eligibility criteria for the catch-up series, the target population (ages 19-26, as the Merck Patient 
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Vaccine Assistance Program will not cover women younger than 19), the background, 
significance, and implications of HPV and its vaccination. Each provider and staff member was 
given a copy of the current CDC and ACIP guidelines, as well as an algorithm of eligibility and 
screening criteria to use as a resource during the project's implementation (see Appendix A). A 
copy of the Merck Patient Vaccine Assistance Program was also given to providers and staff 
members in English (see Appendix B) and Spanish (see Appendix C), so that all staff would be 
familiar with the application, and understand how to properly complete the forms. Staff was also 
given an educational flyer with information about HPV and statistics obtained from The 
American College of Obstetricians and Gynecologists (ACOG) (2017). The obtained flyer was 
free for public use, and was identified within a tool kit promoting the HPV vaccination (see 
Appendix D). Prior to implementation of the new HPV vaccination protocol, an additional one-
on-one educational session was conducted with providers and staff discussing the different roles 
and responsibilities to be completed during the project's implementation.  
 Starting the day before project implementation, medical records personnel placed a 
Merck Patient Vaccine Application in each female patient's chart who was identified between 
19-26 years of age. The provider portion of the application was pre-filled out, and the application 
was placed in the chart according to provider, and whether the patient spoke English or Spanish. 
The application was completed, along with the patient's routine registration packet. Once the 
application was completed, it was then given to the medical assistant during patient intake. The 
medical assistant surveyed the quality improvement tab in the Athena EHR system to check and 
see if the patient had received the HPV vaccination and how many doses, and would then 
confirm this information with the patient during intake. The medical assistant also assessed for 
pregnancy status, as well as allergies to yeast, or a reaction to a previous dose of the HPV 
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vaccination. If no contraindications were identified, the medical assistant would place a "vaccine 
eligible" tab in front of the patient's paper chart, which housed the super bill. The provider was 
then provided with the application, so a signature could be obtained. The medical assistant then 
faxed the application to Merck.  
 Approval from Merck took approximately 10-30 minutes, so the sooner the application 
was faxed, the greater the chance of the patient receiving the vaccination during their visit. When 
the providers entered the examination rooms for the patient visits, they reassessed for 
contraindications to the HPV vaccination, if previous doses had been received, and then provided 
a strong recommendation in favor of the receiving the HPV vaccination. If the application was 
approved, no contraindications were noted, and the patient was eligible for the vaccination, the 
vaccination was then administered.  
 Post-administration, the providers wrote either a diagnosis of administered immunization: 
Gardasil 9-valent in the EHR, along with clicking the quality improvement tab in the EHR, and 
specifying the dates of vaccination administration, or wrote, "patient declined Gardasil 
vaccination," and then provided the patient will educational materials. In the event where the 
application was approved, but the patient had to leave, or the office was out of vaccinations, the 
applications were held for a total of 30 days; The patient was then scheduled for a nurse visit and 
received the vaccination at a later date. Patients were scheduled for nurse visits to receive 
subsequent doses of the HPV vaccination, or when the clients declined the HPV vaccination, 
they were told if they change their mind, to call and schedule a nurse visit for the vaccination. 
 A list was kept of females who had initiated the vaccination series, but did not schedule a 
nurse visit for when their next dose would be due. The licensed vocation nurses then called and 
scheduled these women prior to when their next dose was due. 
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 Following implementation of the new HPV vaccination protocol, all patients ages 19-26 
years of age, who entered the office during the 10 weeks of project implementation, were 
included in the post-intervention data and analysis. There were a total of 50 patients seen at the 
clinic during the 10 week implementation duration. All patients were tracked throughout each 
step of the protocol, from the first week of implementation, through the tenth week and the 
project's end. 
 Prior to the initiation of this quality improvement project, the proposed plan was 
submitted to both the University of the Incarnate Word's Institutional Review Board (IRB), as 
well as the Christus Health IRB for approval. The project was approved by exempt review, as it 
was determined to be less than minimal risk to those participating, and no known physical, 
emotional, psychological, or economic risk for the individual participating. 
Organizational Barriers and/or Facilitators 
 Throughout the project's implementation, multiple obstacles were faced with the 
implementation of the new protocol. Barriers included failure to screen patients, fluctuations 
with the patient population seen due to provider's absence during the implementation period, 
patient misconceptions, patients previously having received the HPV vaccination, and EHR 
charting not reflective of this, as well as missing vaccination doses and receiving these in a 
timely fashion. The first dose of clinic vaccinations received were short two doses, which were 
needed for the initial ten. The initial clinic-purchased vaccinations to begin the project were 
received June 5, 2017. The licensed vocational nurses and the office manager made daily calls to 
the manager of the hospital's pharmacy to retrieve the missing doses. Vaccinations were 
delivered July 7, 2017. Multiple opportunities were missed to administer patient vaccinations 
during this time.  
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 The first week, medical personnel did not include the Merck application on all patients 
who were eligible. Reinforcement and clarification was provided, which improved the problem.  
 Other problems identified included the medical assistants not filling out the form in its 
entirety, and incorrectly. Additional education and reinforcement was provided.  
 Some patient misconceptions occurred, as some did not see a need for the vaccination, 
did not want an injection, or had a knowledge deficit regarding the HPV vaccination. Most 
patients, once provided educational material, and the knowledge that this vaccination helps 
prevent cervical cancer, were eager to obtain vaccination status. Other misconceptions included a 
patient's lack of knowledge if they'd previously received the vaccination during childhood, and 
did not have their immunization card available.  
 Facilitators to the implementation of the quality improvement project included a strong 
rapport with staff, eagerness to take on a new role and responsibility, staff empowerment through 
knowledge, and providing staff with an opportunity to empower patients through education. 
Furthermore, consideration was taken to consider the clinic staff's input in regards to how to 
successfully implement this project. The clinic staff was familiar with the processes and 
procedures of contacting and scheduling patients for visits, and follow-ups, which assisted in 
smoothly implementing the project. Furthermore, as other vaccinations are given at the clinic, the 
staff is familiar with the process of obtaining consent, administering vaccinations, and tracking 
the vaccinations administered.  
 A major facilitator of this project was the clinic and staff's buy-in. By increasing patient 
visits with either the nurse or provider, and the overall volume of patients seen, clinic numbers 
are increased. This helped the clinic to maintain or increase yearly funding. Over the last few 
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years, the clinic has not met the annual numbers needed to maintain or increase funding, so 
funding to provide care to high acuity patients has decreased. 
 Another facilitator of this project was the ease and timeliness of working with the Merck 
Patient Vaccine Assistance Program. This will be a large contributing factor to the sustainability 
of this project once the implementation period is over. 
Results 
 From June 2017 to August 2017, 50 women were identified who were eligible to receive 
the HPV vaccination. Of these women, 13 received the HPV vaccination, 1 was not approved by 
the Merck Patient Assistance Vaccination Program, 23 were unable to receive the vaccination due 
to the vaccine being out of stock, 8 were previously vaccinated, but it had not been documented in 
the EMR, and 5 women refused the vaccination. The pre-intervention group also consisted of 50 
women. 
 A Fisher's Exact Test was conducted on each of the pre-intervention and post-intervention 
variables. The test results indicated the two groups did not differ significantly in age, marital status, 
insurance, race, UTD on pap smear, contraceptive method used, history of a STI, or level of 
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Descriptive Characteristics of Pre and Post-Intervention Groups 
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 A chi-square analysis was conducted to determine significance between the pre-
intervention and post-intervention groups. The percentage of patients receiving one or more 
doses of the HPV vaccination were found to differ significantly between the pre-intervention and 
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Contingency Table Analysis of HPV Vaccination Doses 






























Likelihood Ratio 26.967 1 .000 .000 .000 
 
 
Fisher's Exact Test 






22.519c 1 .000 .000 .000 .000 
 
 
N of Valid Cases 101  
 
    
 
 
A contingency table analysis was completed with the Chi-Square Statistic to test for a. 0 cells 
(0.0%) have expected count less than 5. The minimum expected count is 10.89 statistical 
significance. The analysis reflects results which are both statistically and clinically significant. 
In the pre-intervention group, 2% of individuals were receiving the HPV vaccination. In the 
post-intervention group, 40% of women seen received one or more doses of the HPV 
vaccination. 
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Figure 1. Pre-Intervention versus post-intervention HPV vaccination rates. 
The provider's adherence to recommending the vaccination, and documenting the 
recommendation, or the patient's refusal of the HPV vaccination in the EMR system, increased 
from 0% to 100%. 
Discussion 
 The purpose of this quality improvement project was to increase the HPV vaccination 
rate among indigent women 19-26 years of age, and increase provider adherence to the ACIP and 
CDC guidelines. During the ten-week implementation phase, an increase of 2% pre-intervention 
to 40% post-intervention was noted. During this time, many women were able to receive one or 
two doses of the HPV vaccination. These percentages are now more closely related to national 
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estimates. Within the United States, approximately 21% of HPV vaccine eligible 19-26 year-old 
women have initiated vaccine uptake (Marchand, Glenn, & Bastani, 2012). However, results 
yielded from this quality improvement indicated that many women who may benefit from 
receiving the HPV vaccination, have not received it (Marchand et al., 2012). 
 The setting where this project took place at serves the indigent population; however, it is 
considered a hospital-based clinic, and therefore, does not qualify to participate in the Adult 
Safety Net Program, nor the Vaccines for Children Program.  Funding was the main obstacle 
throughout this endeavor. Many eligible women who received the vaccination were unaware it 
existed, was needed, or could be given at a younger age. Furthermore, consistent access to the 
vaccine was a dilemma.  
 This project was made possible by educating the clinic's office manager, and providers, 
on the Merck Patient Vaccine Assistance Program, and the benefits it could have for the patients 
seen in the clinic. By participating in this cost-assistance program, the clinic was required to 
purchase and stock 10 doses of the HPV vaccination. Merck then provided the Gardasil 
vaccination to the clinic for low-income adults through the Patient Vaccine Assistance Program. 
This clinical setting was fortunate enough to afford to stock these initial 10 vaccines. Without 
this, this strategy would not have been viable. 
 Furthermore, provider recommendation played a large role in increasing the number of 
women initiating the HPV vaccination. Prior to this intervention, the providers were not 
recommending the HPV vaccination; however, post-intervention, 50 out of 50 charts reflected 
documentation from the clinic's providers that they had recommended, and given educational 
material regarding the HPV vaccination. By recommending the vaccination, rather than offering 
it, research has shown that this simple intervention has had marked increases in HPV vaccine 
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uptake.            
 Other research has shown that younger age was a predictor of greater vaccine uptake 
(Marchand et al., 2012). The mean age in both the pre-intervention and post-intervention groups 
of this study who initiated vaccine uptake was 22 years of age.  
Limitations 
 The main limitation was the lack of time for the project's implementation. The project 
implementation period was 10 weeks, which is enough time to receive one vaccination, and 
maybe a second. The overall volume of patients in the target age range (19-26), as well as the 
eligibility screening rates may have been affected by fluctuations in the clinic's providers' 
schedules, as well as multiple office staff members and providers on vacation during this time 
frame. Furthermore, due to the timing of implementation (summer), the Merck Patient Vaccine 
Assistance representative for Texas was unable to deliver the next shipment of the Gardasil-9 
vaccinations to the clinic within the project's implementation time frame, as this individual was 
on vacation at this time. 
Recommendations 
 Though adherence and compliance rates were increased to levels that were both clinically 
and statistically significant, more improvements can be made. The clinic should continue to 
utilize the Merck Patient Vaccine Assistance Program, ensuring that all women who are able to 
receive the HPV vaccination receive it. Further recommendations would be to include a longer 
implementation period, not taking place during summer months when providers and patients may 
be on vacation. Comparing the rates of vaccination in the Summer months to the rates during the 
Spring and Fall may be an additional way to increase vaccination compliance and adherence. 
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Lastly, following up with the Merck Patient Assistance Vaccination Program frequently may 
ensure HPV vaccinations are delivered to the clinic in a timely fashion. 
Implications for Practice 
There were 1/50 (2%) patients given the HPV vaccination in the pre-intervention patient 
population. Of the patients screened for eligibility during the project implementation, there were 
20/50 (40%) given one or more doses of the HPV vaccination. The results of this QI project 
demonstrated that by training staff and providers on the most up-to-date guidelines, and utilizing 
patient assistance programs, HPV vaccination rates in indigent women ages 19-26 can increase. 
Based on these results, one could conclude that other primary care practices who offer services to 
the indigent population could benefit from screening women who may be eligible for the HPV 
vaccination, provider recommendation, utilizing the Merck Patient Vaccine Assistance Program, 
and administering the vaccination.        
 Other clinics, such as women's and men's health clinics, gynecologists office, college 
health centers, and specialty clinics of this nature could also benefit by implementing a HPV 
vaccination protocol, and utilizing the Merck Patient Vaccine Assistance Program.               
 The advanced practice registered nurse is in a unique position to offer insight, oversight, 
and assist in implementing measures which may increase patient outcomes and quality of care. In 
this circumstance, implementing the CDC and ACIP's guidelines to screen and vaccinate women 
who are eligible to receive the HPV vaccination, has the potential to significantly impact 
individuals who are at an increased risk for acquiring the human papillomavirus and cervical 
cancer. A cornerstone of the advanced practice registered nurse's education focuses on health 
promotion, disease prevention, and patient education. By utilizing and implementing a protocol 
to properly screen women who may be eligible for the HPV vaccination, and providing a strong 
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recommendation in favor of the vaccination, the advanced practice registered nurse has the 
potential to decrease rates of cancer, and improve the health and quality of lives of their patients, 
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HPV Vaccination Screening Eligibility Protocol 
 
 
For ALL female patients: 
 
1.) Is the patient between 19-26 years of age? If yes, continue to item 2. 
 
2.) Has the woman received any doses of the HPV vaccination? Ask patient, and check quality 
tab in Athena. 
 
3.) If NO, ask about allergies to yeast. If no allergies to yeast, continue to step 4. 
 
4.) Have patient complete Merck Patient Vaccination Assistance Application, and fax application 
to Merck, 1-800-528-2551. 
 
5.) ***REMIND PROVIDER TO RECOMMEND THE HPV VACCINATION*** 
 
6.) If YES, how many doses has patient received? If 3 doses, stop. If less than 3 doses, continue. 
 
7.) Has patient ever had an allergic reaction to the HPV vaccination? If no, continue to step 8. 
 
8.) Have patient complete Merck Patient Vaccination Assistance Application, and fax application 
to Merck, 1-800-528-2551. 
 
9.) ***REMIND PROVIDER TO RECOMMEND THE HPV VACCINATION*** 
 
 
*GUIDELINES* (CDC, 2014; CDC, 2015) 
 
The three-dose series should be given to those persons who initiate the vaccine at > 15 years of 
age, as well as individuals who are immunocompromised. The schedule of the 3-dose series is: a 
vaccination given at the initial visit, one given two months after the first vaccination, and one 
given six months after this. The HPV ’catch-up’ series should be initiated on persons 13-26 years 
of age. 
 
*For this project: only screen women ages 19-26. 
*Other names for the HPV vaccination include: Gardasil, Gardasil 9, Gardasil 9 valent, 
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Merck Patient Vaccine Assistance Application - Spanish 
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Appendix C. Continued - Merck Patient Vaccine Assistance Application - Spanish 
 
 




The HPV Vaccine is a Lifesaver Flyer 
 
